EMERGENT BIOSOLUTIONS INC. Notes Payable, Current
EMERGENT BIOSOLUTIONS INC. (EBS) had Notes Payable, Current of $0 as of 2024-12-31, per its 10-K filed 2025-03-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Long-Term Debt, Current Maturities
us-gaap:NotesPayableCurrent · last filed 2025-03-04
- 2024-12-31: Notes Payable, Current $0.00.
- 2024-09-30: Notes Payable, Current $800.00K.
- 2024-06-30: Notes Payable, Current $415.20M.
- 2024-03-31: Notes Payable, Current $459.20M.
| Period end | Notes Payable, Current |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-04 |
| 2024-09-30 | $800.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $415.20M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $459.20M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $413.70M 10-K · filed 2025-03-04 |
| 2023-09-30 | $413.60M 10-Q · filed 2023-12-11 |
| 2023-06-30 | $455.20M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $950.70M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $957.30M 10-K · filed 2024-03-08 |
| 2022-09-30 | $21.20M 10-Q · filed 2023-12-11 |
| 2022-06-30 | $31.60M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $31.60M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $31.60M 10-K/A · filed 2023-12-11 |
| 2021-09-30 | $31.60M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $28.80M 10-Q · filed 2021-07-30 |
| 2021-03-31 | $26.00M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $33.80M 10-K · filed 2022-02-25 |
| 2020-09-30 | $30.90M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $29.10M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $26.30M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $12.90M 10-K · filed 2021-02-19 |
| 2018-12-31 | $10.10M 10-K · filed 2020-02-25 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-22 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-03 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-04 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 |
| 2016-12-31 | $20.00M 10-K · filed 2018-02-23 |
| 2016-09-30 | $20.00M 10-Q · filed 2016-11-09 |
| 2015-12-31 | $0.00 10-K · filed 2017-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |